<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03876938</url>
  </required_header>
  <id_info>
    <org_study_id>728/2561(EC4)</org_study_id>
    <nct_id>NCT03876938</nct_id>
  </id_info>
  <brief_title>Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy</brief_title>
  <official_title>Randomized, Placebo-controlled Trial of Olanzapine Versus Aprepitant Plus Ondansetron and Dexamethasone as Antiemetic Prophylaxis in Patients Receiving High Emetic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aprepitant and olanzapine have been recommended for emesis prevention from highly emetogenic
      chemotherapy. We hypothesized that olanzapine may lead to less nausea compared to aprepitant
      based on previous study. However, data of combination of olanzapine and ondansetron is
      scarce.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aprepitant and olanzapine have been recommended for emesis prevention from highly emetogenic
      chemotherapy. We hypothesized that olanzapine may lead to less nausea compared to aprepitant
      based on previous study. However, data on efficacy and adverse effects of combination of
      olanzapine and ondansetron which is only serotonin antagonist in Thai national essential drug
      list, is scarce. Also, we aims to assess the efficacy of olanzapine dosage of 5 mg which is
      more commonly used in Thai patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>no nausea rate</measure>
    <time_frame>Days 1-5 of chemotherapy</time_frame>
    <description>proportion of patients report no nausea</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete remission</measure>
    <time_frame>Days 1-5 of chemotherapy</time_frame>
    <description>no episode of vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&gt;= grade 3 vomiting</measure>
    <time_frame>Days 1-5 of chemotherapy</time_frame>
    <description>higher than grade 3 vomiting</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">147</enrollment>
  <condition>Antiemetic for Highly Emetogenic Chemotherapy</condition>
  <arm_group>
    <arm_group_label>aprepitant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aprepitant / dexamethasone/ ondansetron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olanzapine 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olanzapine 10 mg/dexamethasone/ ondansetron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olanzapine 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olanzapine 5 mg/dexamethasone/ ondansetron</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aprepitant</intervention_name>
    <description>aprepitant 125 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy aprepitant 80 mg orally D2-4, dexamethasone 8 mg/day orally D2-4</description>
    <arm_group_label>aprepitant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine 10 mg</intervention_name>
    <description>olanzapine 10 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy olanzapine 10 mg orally D2-4, dexamethasone 8 mg/day orally D2-4</description>
    <arm_group_label>olanzapine 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine 5 mg</intervention_name>
    <description>olanzapine 5 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy olanzapine 5 mg orally D2-4, dexamethasone 8 mg/day orally D2-4</description>
    <arm_group_label>olanzapine 5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathologically proved of solid malignancy

          -  receive first cycle of cisplatin &gt;= 50 mg/m2 or cyclophosphamide/doxorubicin

        Exclusion Criteria:

          -  pregnancy

          -  patients with episode of vomiting within 24 hours before starting chemotherapy

          -  uncontrolled brain/ CNS metastasis

          -  gut obstruction

          -  receive combination of moderate or high emetogenic chemotherapy during Day 2-5

          -  Known allergy to ondansetron, olanzapine, aprepitant or dexamethasone

          -  currently receive olanzapine with other indication and plan to continue the drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suthinee Ithimakin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suthinee Ithimakin, MD</last_name>
    <phone>+6624194489</phone>
    <email>aesi105@yahoo.co.th</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of medical oncology, department of medicine Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suthinee Ithimakin, MD</last_name>
      <phone>662-419-4489</phone>
      <email>aesi105@yahoo.co.th</email>
    </contact>
    <investigator>
      <last_name>Suthinee Ithimakin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pathra Theeratrakul, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Apirom Laocharoenkiat</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charuwan Akewanlop, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Akarin Nimmannit, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suthinee Ithimakin, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

